Nextage Therapeutics Ltd Cash Flow Conversion Efficiency
Nextage Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Nextage Therapeutics Ltd (NXTG) has a cash flow conversion efficiency ratio of -0.730x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.72 Million ≈ $-4.61K USD) by net assets (ILA2.36 Million ≈ $6.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nextage Therapeutics Ltd (2017–2024)
Cash flow conversion efficiency of Nextage Therapeutics Ltd from 2017 to 2024. This chart illustrates how Nextage Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nextage Therapeutics Ltd share price for real-time trading data and today's change.
Nextage Therapeutics Ltd Cash Flow Conversion Ratio Explained
Nextage Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nextage Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nextage Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see how much is Nextage Therapeutics Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Techstep ASA
OL:TECH
|
0.098x |
|
Witbe Net SA
PA:ALWIT
|
0.366x |
|
Westbond Enterprises Corp
V:WBE
|
0.025x |
|
PT Sunter Lakeside Hotel Tbk
JK:SNLK
|
0.004x |
|
Sejin T.S Co.Ltd
KQ:067770
|
0.010x |
|
Baird Medical Investment Holdings Limited
NASDAQ:BDMD
|
-0.090x |
|
GUILD ESPORTS PLC LS-001
F:GU0
|
N/A |
|
Surya Biru Murni Acetylene Tbk PT
JK:SBMA
|
0.017x |
Annual Cash Flow Conversion Efficiency for Nextage Therapeutics Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nextage Therapeutics Ltd from 2017 to 2024. Review NXTG financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA-5.54 Million ≈ $-14.84K |
ILA-795.00K ≈ $-2.13K |
0.144x | -82.62% |
| 2023-12-31 | ILA-2.74 Million ≈ $-7.34K |
ILA-2.26 Million ≈ $-6.06K |
0.826x | -94.14% |
| 2022-12-31 | ILA-426.00K ≈ $-1.14K |
ILA-6.01 Million ≈ $-16.12K |
14.113x | +283.24% |
| 2021-12-31 | ILA516.00K ≈ $1.38K |
ILA-3.97 Million ≈ $-10.65K |
-7.702x | -76.95% |
| 2020-12-31 | ILA1.45 Million ≈ $3.89K |
ILA-6.31 Million ≈ $-16.92K |
-4.352x | -442.90% |
| 2019-12-31 | ILA3.66 Million ≈ $9.80K |
ILA-2.93 Million ≈ $-7.86K |
-0.802x | -126.70% |
| 2018-12-31 | ILA-1.65 Million ≈ $-4.42K |
ILA-4.95 Million ≈ $-13.28K |
3.003x | +334.96% |
| 2017-12-31 | ILA4.44 Million ≈ $11.90K |
ILA-5.67 Million ≈ $-15.20K |
-1.278x | -- |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.